Long noncoding RNA MEG3 blocks telomerase activity in human liver cancer stem cells epigenetically

Xiaoxue Jiang  
Tongji University

Liyan Wang  
Tongji University

Sijie Xie  
Tongji University

Yingjie Chen  
Tongji University

Shuting Song  
Tongji University

Yanan Lu  
Tongji University

Dongdong Lu  (ludongdong@tongji.edu.cn)  
Tongji University  https://orcid.org/0000-0002-7417-4172

Research

Keywords: liver cancer stem cell, MEG3, P53, HP1α, HULC, TERT, Telomere

DOI: https://doi.org/10.21203/rs.3.rs-57936/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

**Background:** MEG3 is down-regulated expression in several tumors and inhibits human tumorigenesis. But so far, the mechanism of MEG3 in tumorigenesis is still unclear.

**Methods:** Gene infection, cellular and molecular technologies and tumorigenesis test *in vitro* and *in vivo* were performed, respectively.

**Results:** our results indicate that MEG3 enhances the P53 expression by triggering the loading of P300 and RNA polymerase II onto its promoter regions dependent on HP1α. Moreover, MEG3 increases the methylation modification of histone H3 at the 27<sup>th</sup> lysine via P53. Furthermore, MEG3 inhibits the expression of TERT by increasing the H3K27me3 in TERT promoter regions. Thereby, MEG3 inhibits the activity of telomerase by reducing the binding of TERT to TERC. Furthermore, MEG3 also increases the expression of TERRA, therefore, the interaction between TERC and TERT was competitively attenuated by increasing the interaction between TERRA and TERT, which inhibits the activity of telomerase in hLCSCs. Strikingly, MEG3 reduces the length of telomere by blocking the formation of complex maintaining telomere length (POT1-Exo1-TRF2-SNM1B) and decreasing the binding of the complex to telomere by increasing the interplay between P53 and HULC. Ultimately, MEG3 inhibits the growth of hLCSCs by reducing the activity of telomerase and attenuating telomeric repeat binding factor 2 (TRF2).

**Conclusions:** Our results demonstrates MEG3 inhibits the occurrence of human liver cancer by blocking telomere and these findings provide an important insight into the prevention and treatment of human liver cancer.

Introduction

It has been found that human stem cells can differentiate into malignant tumor stem cells (1-3). At present, extensive research has been conducted on the mechanism of driving stem cell deterioration, such as METTL3-eIF3h-mediated mRNA circulation promotes stem cell deterioration (4) and FXR regulates the proliferation of small intestinal cancer stem cells (5). Interleukin 22 protects intestinal stem cell resistance genotoxicity (6) and C-Myc enhancer promotes the proliferative capacity of leukemia stem cells (7). Studies have confirmed that there are liver cancer stem cells in human liver cancer tissues, which have stem cell characteristics such as self-renewal and differentiation (8). At present, it is not clear what causes the accumulation of stem cell genetic errors, chromosome instability and telomere function, and eventually evolve into cancer stem cells.

Telomeres are a special structure of eukaryotic chromosome ends consisting of many simple repeats and related proteins rich in guanine (9). Telomere-associated protein complexes include TRF1, TRF2, Rap1, POT1, TIN2, and TPP1 (10). TRF1 regulates the replication of telomeric DNA and TRF2 is involved in the formation of the T-loop (11). The telomerase core components include telomerase reverse transcriptase (TERT) and telomerase RNA (TERC). TERT is a catalytic subunit, and TERC is an RNA template during telomere extension (12, 13). Increased telomerase activity is associated with increased
copy number of the telomerase (14). Moreover, telomerase is involved in stem cell self-renewal (15). Given the important role of telomere length in the proliferation of tumor cells, the researchers propose to treat cancer by inhibiting the elongation of telomeres (16). Studies have shown that telomeres exhibit high levels of histone H3K9me3 and H4K20me3 modifications (17), and that telomeres can be transcribed by RNA polymerase II to generate long-chain non-coding RNA TERRA (Telomeric Repeat-Containing RNA) (18,19). It was found that TERRA was involved in the formation of heterochromatin at the end of the chromosome (20). In addition, the TERRA can bind to TERC through the principle of base-complementary pairing, competitively inhibiting telomerase activity (21). However, studies have found that nuclear heterogeneous ribonucleoprotein A1 (hnRNPA1) binds to TERRA, which blocks the binding of TERRA to telomerase and activates telomerase (22). Moreover, selective extension of telomeres by DNA break induced replication (23-25). In addition, telomere necrosis activates autophagic death (26) and telomeres have certain epigenetic characteristics (27). Studies have also found that telomerase is recruited to the telomere, which is driven by the rapid interaction of telomerase (28).

Long non-coding RNA is involved in the regulation of various growth and development processes in organisms (29). For example, MEG3 silencing can induce mouse pluripotent stem cells (30) and inhibits activation of liver satellite cells (31). MEG3 acts as a ceRNA to regulate hepatic fat metabolism (32). Studies have shown that the expression patterns of various transcriptional variants of MEG3 are tissue-specific (33). In addition, current research indicates that MEG3 is involved in tumorigenesis (34-37). And MEG3 was also found to inhibit prostate cancer progression (38), breast cancer progression by activating NF-κB and p53 (39). MEG3 and progression of osteosarcoma (40). But so far, the mechanism of MEG3 in tumorigenesis is still unclear.

In this study, the human suppressor gene P53 was found to interact with MEG3, which promoted chromatin remodeling and led to changes in telomere function. Under normal conditions, the amount of P53 expression in cells is maintained at a low level. However, cellular stress stimulates an increase in P53 expression (41-45). Also, the study was involved heterochromatin 1 (HP1), which was thought to bind to interstitial Heterochromatin (PCH)-mediated gene silencing, and subsequent studies have found it involved in many other biological processes (46-49). Numerous studies have shown that HP1α is involved in the regulation of epigenetic modifications of cancer-associated genes, which in turn affects tumor development (50-53). Furthermore, EZH2, EED, and SUZ12 are ubiquitously expressed in rectal cancer cells, and their expression is positively correlated with tumor malignancy and poor prognosis (54).

In this study, MEG3 inhibits human liver cancer stem cells and is involved in epigenetic regulation for histones and telomere lifespan. The decrease of telomerase activity and telomere stability is an important reason for MEG3 to inhibit the growth of human liver cancer stem cells.

Methods

Human liver cancer stem cell line (hLCSC) sorting CD133/CD44/CD24/EpCAM MicroBead Kits were purchased from Miltenyi technic(Boston,USA) and MACS® Technology operation according to and the
Cell Lines, Lentivirus and Plasmids  Human liver cancer stem cell line (hLCSC) was maintained in Minimum Essential Medium (MEM) (Gibco BRL Life Technologies) in a humidified atmosphere of 5% CO₂ incubator at 37°C. rLV, rLV-Cas9 were purchased from Wu Han viraltherapy Technologies Co. Ltd. pCMV6-A-GFP, pGFP-V-RS and pMirTarget-3’UTR pMirTarget-3’UTR were purchased from Origene (Rockville, MD,USA). pCMV6-A-GFP-MEG3, pGFP-V-RS-C-MEG3, pGFP-V-RS-TERT and pMartarget-3’UTR-C-TERT promoter were cloned by ourselves.

Cell infection and transfection. Cells were infected with Lentivirus and transfected with DNA plasmids using transfast transfection reagent lipofectamine® 2000 (Invitrogen) according to manufacturer's instructions.

RT-PCR Total RNA was purified using Trizol (Invitrogen) according to manufacturer's instructions. cDNA was prepared by SuperScript First-Strand Synthesis System (Invitrogen). PCR analysis was performed according to manufacturer's instructions. β-actin was used as an internal control.

Co-immunoprecipitation(IP) The cell lysates was used in immunoprecipitation with related antibodies. Western blot was performed with a another related antibody indicated in Western blotting according to the manufacturer's instructions.

Chromatin immunoprecipitation (CHIP) assay Cells were cross-linked with 1% (v/v) formaldehyde (Sigma) for 10 min at room temperature and stopped with 125 mm glycine for 5 min. Crossed-linked cells were washed with phosphate-buffered saline, resuspended in lysis buffer, and sonicated for 5 min. Chromatin extracts were pre-cleared with Protein-A/G-Sepharose beads, and immunoprecipitated with specific antibody on Protein-A/G-Sepharose beads. After washing, elution and de-cross-linking, the ChIP DNA was detected by PCR according to the manufacturer's instructions.

Chromosome conformation capture (3C)-chromatin immunoprecipitation (ChIP) Chromatin bound to the antibody-Protein-A/G-Sepharose beads were resuspended and the ChIP-3C material was detected for long range interaction with specific primers according to the manufacturer's instructions.

Super-EMSA(Gel-shift) Cells were washed and scraped in ice-cold PBS to prepare nuclei for electrophoretic gel mobility shift assay with the use of the gel shift assay system modified according to the manufacturer's instructions (Promega).

Cells proliferation CCK8 Assay The cell proliferation reagent CCK8 is purchased from Roch and the operation according to the manufacturer instruction.

Colony formation ability Assay cells were plated on the dish and the DMEM containing 10%FBS was added into each dish (three replicate). Cell colonies on the dishes were stained with 1 ml of 0.1% Crystal Violet according to the manufacturer's instructions.
Xenograft transplantation in vivo The male athymic Balb/C mice per group were injected with liver cancer stem cells at the armpit area subcutaneously. The mice were observed over four weeks, and then sacrificed to recover the tumors. The use of mice for this work was reviewed and approved by the institutional animal care and use committee in accordance with China national institutes of health guidelines.

**Results**

**MEG3 inhibits the growth of human liver cancer stem cells**

To investigate whether MEG3 affects the growth of human liver cancer stem cells (hLCSCs), First, hLCSCs were isolated from Huh7 cells using CD133/CD44/CD24/EpCAM microbeads. The four plasmids (pCMV6-A-GFP-MEG3, pCMV6-A-GFP, pGFP-V-RS-MEG3 and pGFP-V-RS) were transfected into hLCSCs, respectively, and positive cells were picked and expanded. MEG3 was significantly increased in pCMV6-A-GFP-MEG3 group compared to the pCMV6-A-GFP group and reduced in pGFP-V-RS-MEG3 group compared to the pGFP-V-RS group (Figure 1A-C). Furthermore, circMEG3 was significantly increased in pCMV6-A-GFP-MEG3 group compared to the pCMV6-A-GFP group and reduced in pGFP-V-RS-MEG3 group compared to the pGFP-V-RS group (Figure 1D). The growth ability was significantly reduced in pCMV6-A-GFP-MEG3 group compared to the pCMV6-A-GFP group and increased in pGFP-V-RS-MEG3 group compared to the pGFP-V-RS group (P<0.01) (Figure 1E). The Brdu positive rate was significantly reduced in pCMV6-A-GFP-MEG3 group compared to the pCMV6-A-GFP group (42.95±3.31% vs 19.66±1.98%, P=0.0072145 < 0.01) and increased in pGFP-V-RS-MEG3 group compared to the pGFP-V-RS group (38.53±2.503% vs 64.59±7.02%, P=0.0087726 < 0.01) (Figure 1F). The colony formation ability was significantly reduced in pCMV6-A-GFP-MEG3 group compared to the pCMV6-A-GFP group (24.62±3.08% vs 15.23±1.87%, P=0.007906<0.01) and increased in pGFP-V-RS-MEG3 group compared to the pGFP-V-RS group (22.9±2.47% vs 48.44±5.30%, P=0.0005529<0.01) (Figure 1Ga&b). The sphere formation ability was significantly reduced in pCMV6-A-GFP-MEG3 group compared to the pCMV6-A-GFP group (14.13±2.42% vs 5.37±0.73%, P=0.00906<0.01) and increased in pGFP-V-RS-MEG3 group compared to the pGFP-V-RS group (16.13±3.26 % vs 30.72±4.34%, P=0.00216 < 0.01) (Figure 1H). The weight of transplanted tumors was significantly reduced in pCMV6-A-GFP-MEG3 group compared with the pCMV6-A-GFP group (0.51±0.044g vs 0.173±0.025g,P=0.0000186<0.01) and increased in pGFP-V-RS-MEG3 group compared to the pGFP-V-RS group (0.465 ± 0.065 g vs 0.96 ± 0.126g, P=0.000000579<0.01) (Figure 1I&J). The appearance time of transplanted tumors was significantly increased in pCMV6-A-GFP-MEG3 group compared with the pCMV6-A-GFP group (7.16±1.72 days vs 15.0 ± 2.09 days, P=0.00000076<0.01) and decreased in pGFP-V-RS-MEG3 group compared to the pGFP-V-RS group (7.50±1.04 days vs 6.0 ± 0.89 days, P=0.0086<0.01) (Figure 1K). The PCNA positive rate in transplanted tumors was significantly decreased in pCMV6-A-GFP-MEG3 group compared with the pCMV6-A-GFP group (40.65±2.88% vs 15.19±3.26%, P=0.0000023<0.01) and increased in pGFP-V-RS-MEG3 group compared to the pGFP-V-RS group (43.64±8.02% vs 72.88±12.71%, P=0.004559 <0.01) (Figure 1L). The Ki67 positive rate in transplanted tumors was significantly decreased in pCMV6-A-GFP-MEG3 group compared with the pCMV6-A-GFP group (30.48±2.76% vs 12.09±3.07%, P=0.000099<0.01) and increased in pGFP-V-
RS-MEG3 group compared to the pGFP-V-RS group (27.73±4.69% vs 44.33±7.24%, P =0.00079 < 0.01) (Figure1M). Collectively, these observations suggest that MEG3 inhibits the growth of human liver cancer stem cells.

**MEG3 enhances the methylation modification of histone H3 at the 27th lysine via P53**

To investigate whether MEG3 affects the methylation modification of histone H3 at the 27th lysine via P53 in liver cancer stem cells, we cross-linked the cells with formaldehyde and then analyzed by chromatin immunoprecipitation (CHIP) with anti-P300 and anti-RNAPolII. The results showed that the binding ability of P300 and RNAPolII to P53 promoter were significantly enhanced in the pCMV6-A-GFP-MEG3 group compared with the pCMV6-A-GFP group and reduced in the pGFP-V-RS-MEG3 group compared with the pGFP-V-RS group (Figure2A). Simultaneously, chromatin immunoprecipitation (CHIP)-3C analysis with anti-P300, anti-RNAPolII was performed. The results showed that the binding capacity of P300 and RNAPolII to P53 promoter-enhancer loops (DNA LOOP) were significantly increased in the pCMV6-A-GFP-MEG3 group compared with the pCMV6-A-GFP group and reduced in the pGFP-V-RS-MEG3 group compared with the pGFP-V-RS group (Figure2B). The activity of pEZX-MT-P53-promoter-Luc reporter gene were significantly enhanced in the pCMV6-A-GFP-MEG3 group compared with the pCMV6-A-GFP group (9753.68±930.63 vs 88000.67±16199.96, p=0.0062527 <0.01) and reduced in the pGFP-V-RS-MEG3 group compared with the pGFP-V-RS group (9404.57±1457.29 vs 2740.33±592.42, p=0.0086264<0.01) (Figure2C). The expression of P53 was significantly increased in the pCMV6-A-GFP-MEG3 group compared with the pCMV6-A-GFP group and reduced in the pGFP-V-RS-MEG3 group compared with the pGFP-V-RS group (Figure 2D-E). Furthermore, the expression of P53 was slightly increased in the pCMV6-A-GFP+pcDNA3-HP1α group and decreased in the pCMV6-A-GFP+pGFP-V-RS-HP1α group compared with pCMV6-A-GFP, and significantly increased in the pCMV6-A-GFP-MEG3+pcDNA3-HP1α group and decreased in the pCMV6-A-GFP-MEG3+pGFP-V-RS-HP1α group compared with the CMV6-A-GFP-MEG3 group (Figure2F). The interaction between MEG3 probe and EZH2, SUZ12, EED, RbAp46/48 was significantly increased in pCMV6-A-GFP-MEG3 group and attenuated in the pCMV6-A-GFP-MEG3+ pGFP-V-RS-P53 group compared with the pCMV6-A-GFP group (Figure2G). The interaction between Histone H3 and EZH2, SUZ12, EED, RbAp46/48 was significantly enhanced in the pCMV6-A-GFP-MEG3 group compared with the pCMV6-A-GFP and reduced in the pGFP-V-RS-MEG3 group compared to the pGFP-V-RS group (Figure2H). Although the interaction of EZH2, SUZ12, EED, RbAp46/48 with histone H3 was increased in the pCMV6-A-GFP-MEG3 group and reduced in the pGFP-V-RS-MEG3 group compared with the pCMV6-A-GFP group, the interaction of EZH2, SUZ12, EED, RbAp46/48 with histone H3 was enhanced in pCMV6-A-GFP+pcDNA3-P53 group , pCMV6-A-GFP-MEG3+pcDNA3-P53 group , pGFP-V-RS-MEG3+pcDNA3-P53 group and attenuated in pCMV6-A-GFP+ pGFP-V-RS-P53 group , pCMV6-A-GFP-MEG3+pGFP-V-RS-P53 group , pGFP-V-RS-MEG3+ pGFP-V-RS-P53 group , respectively (Figure2I). Ultimately, H3K27me1, H3K27me2 and H3K27me3 was significantly increased in the pCMV6-A-GFP-MEG3 group compared to the c pCMV6-A-GFP group and reduced in the pGFP-V-RS-MEG3 group compared to the pGFP-V-RS group (Figure2Ja&b). Collectively, these results suggest that MEG3 enhances the methylation modification of histone H3 at the lysine 27 through P53 in human liver cancer stem cells.
MEG3 inhibits telomerase activity by increasing TERRA dependent on P53 and HP1α

In view of the fact that MEG3 promotes the methylation of histone H3 lysine at 27th dependent on P53, we first consider whether MEG3 affects the expression of telomerase reverse transcriptase (TERT) via H3K27me3 in liver cancer stem cells. The binding ability of H3K27me3 to the TERT promoter DNA probe was significantly increased in pCMV6-A-GFP-MEG3 group and reduced in pGFP-V-RS-MEG3 group compared to control. On the contrary, the binding ability of RNA polII to the TERT promoter DNA probe was significantly decreased in pCMV6-A-GFP-MEG3 group and increased in pGFP-V-RS-MEG3 group compared to control (Figure3A). Super-gel migration assay showed that the binding ability of H3K27me3 to the TERT promoter was significantly increased in pCMV6-A-GFP-MEG3 group and reduced in pGFP-V-RS-MEG3 group compared to control (Figure3B). The binding of H3K27me1, H3K27me2, H3K27me3 to TERT promoter was significantly increased in pCMV6-A-GFP-MEG3 group and reduced in pGFP-V-RS-MEG3 group compared to control (Figure3C). Moreover, TERT promoter luciferase reporter gene activity was decreased in pCMV6-A-GFP-MEG3 group (16199.33±2720.78 vs 4495.34±11119.53, p=0.007278<0.01) and reduced in pGFP-V-RS-MEG3 group compared to control (14740.67±1848.91 vs 208068.0±20781.62, p=0.00218 <0.01) (Figure3D). Moreover, the expression of TERT was decreased in pCMV6-A-GFP-MEG3 group and increased in pGFP-V-RS-MEG3 group compared to control (Figure3E&F). The binding ability of TERT to TREC RNA probe was significantly reduced in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group and increased in pGFP-V-RS-MEG3 group compared to pGFP-V-RS group. In contrast, the binding ability of P53 or HP1α to TREC RNA probe was significantly increased in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group and reduced in pGFP-V-RS-MEG3 group compared to pGFP-V-RS group (Figure3G). Although the binding ability of TERT to TREC probe was significantly reduced in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group and increased in pGFP-V-RS-MEG3 group compared to pGFP-V-RS group, P53 knockdown abrogated this action of MEG3 in hLCSCs (Figure3Ha&b). The binding ability of TERT to TREC was significantly reduced in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group and increased in pGFP-V-RS-MEG3 group compared to pGFP-V-RS group. In contrast, the binding ability of P53 or HP1α to TREC was significantly increased in the pCMV6-A-GFP-MEG3 group and reduced in the pGFP-V-RS-MEG3 group compared with the pCMV6-A-GFP group. The binding ability of TERT to TREC was significantly reduced in pCMV6-A-GFP-MEG3 group and was increased in the pGFP-V-RS-MEG3 group compared with the pCMV6-A-GFP group. The binding ability of P53 or HP1α to TREC probe was enhanced in pCMV6-A-GFP+pcDNA3-P53, pCMV6-A-GFP-MEG3+pcDNA3-P53, pGFP-V-RS-MEG3+pcDNA3-P53 respectively and significantly attenuated in pCMV6-A-GFP+pGFP-V-RS-P53, pCMV6-A-GFP-MEG3+ pGFP-V-RS-P53, pGFP- V-RS-MEG3+ pGFP-V-RS-P53, pCMV6-A-GFP-MEG3+pGFP-V-RS-P53, pGFP-V-RS-MEG3+pGFP-V-RS-P53, pGFP-V-RS-MEG3+ pGFP-V-RS-P53, pGFP-V-RS-MEG3+ pGFP-V-RS-P53 respectively (Figure3J&K). Therefore, the telomerase activity was significantly increased in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP.
MEG3 inhibits telomere stability by promoting the interaction between P53 and long noncoding RNA HULC.
Given that studies have shown that POT1, Exo1, SNM1B, TRF2, and CST/AAF are important related proteins that maintain telomere length, we will try to analyze whether MEG3 has an effect on these proteins. The interaction between CST/AAF and POT1 was significantly increased in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group and decreased in pGFP-V-RS-MEG3 group compared to pGFP-V-RS group, and the interaction between TRF2 and SNM1B was significantly weakened in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group and increased in pGFP-V-RS-MEG3 group compared to pGFP-V-RS group, and the binding ability of CST/AAF to the telomeric DNA probe was significantly increased in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group and decreased in pGFP-V-RS-MEG3 group compared to pGFP-V-RS group (Figure 5A). Moreover, the binding ability of POT1, Exol, TRF2, SNM1B to the telomeric DNA probe was significantly decreased in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group and increased in pGFP-V-RS-MEG3 group compared to pGFP-V-RS group, and the binding ability of CST/AAF to the telomeric DNA probe was significantly increased in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group and decreased in pGFP-V-RS-MEG3 group compared to pGFP-V-RS group (Figure 5B). The binding ability of POT1, Exol, TRF2, SNM1B, HP1α to telomeric DNA was significantly reduced in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group and increased in pGFP-V-RS-MEG3 group compared to pGFP-V-RS group, and the binding ability of CST/AAF to telomeric DNA was significantly increased in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group and decreased in pGFP-V-RS-MEG3 group compared to pGFP-V-RS group (Figure 5C). Furthermore, the binding ability of P53 to HULC was significantly enhanced, and the binding ability of POT1, Exol, TRF2, SNM1B and HULC was significantly reduced in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group. On the contrary, the binding ability of P53 to HULC was significantly reduced, and the binding ability of POT1, Exol, TRF2, SNM1B and HULC was significantly enhanced in pGFP-V-RS-MEG3 group compared to pGFP-V-RS group (Figure 6A). Compared to control group, the binding ability of P53 to HULC was significantly increased in the pCMV6-A-GFP-MEG3 group and pCMV6-A-GFP-MEG3+pCMV6-A-GFP-HULC group, and reduced in the pGFP-V-RS-MEG3 group and pGFP-V-RS-MEG3+ pGFP-V-RS-HULC group. And it was not significantly altered in pCMV6-A-GFP-MEG3+pGFP-V-RS-P53 and pGFP-V-RS-MEG3+pCMV6-A-GFP-P53 compared to control group (Figure 6B). Moreover, the binding ability of POT1, Exol, TRF2, SNM1B to telomeric DNA was significantly reduced and the binding ability of CST/AAF to telomeric DNA was significantly increased in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group, and the binding ability of POT1, Exol, TRF2, SNM1B to telomeric DNA was increased and the binding ability of CST/AAF to telomeric DNA was not significantly altered in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group. However, the binding ability of POT1, Exol, TRF2, SNM1B, CST/AAF to telomeric DNA was not significantly altered in pCMV6-A-GFP-MEG3 group compared to pCMV6-A-GFP group, pCMV6-A-GFP-MEG3+pCMV6-A-GFP-HULC group, pGFP-V-RS-MEG3+ pCMV6-A-GFP-P53 group and pGFP-V-RS-MEG3+ pGFP-V-RS-HULC group (Figure 6C). Super-EMSA results showed that the binding ability of TRF2 to telomere DNA probe was significantly reduced in pCMV6-A-GFP-MEG3 group compared with the pCMV6-A-GFP group and increased in the pGFP-V-RS-MEG3 group compared with the pGFP-V-RS group. However, it was significantly not altered in the pGFP-V-RS-MEG3 group compared to pCMV6-A-GFP group and pGFP-V-RS-HULC group (Figure 6Da&b). The length of telomere was significantly reduced in the pCMV6-A-GFP-MEG3 group compared with the pCMV6-A-GFP group and increased in the pGFP-V-RS-MEG3 group compared to pGFP-V-RS group (Figure 6E). In addition, the quantitative analysis showed telomere length was significantly reduced in pCMV6-A-GFP-MEG3 group compared to the pCMV6-A-GFP group (1.44±
0.289 vs 0.213±0.045; P=0.00673<0.01) and increased in the pGFP-V-RS-MEG3 group compared with the pGFP-V-RS group (1.413±0.165 vs 3.51 ± 0.424; P = 0.00778 < 0.01) (Figure 6F). Although the length of telomere was significantly reduced in the pCMV6-A-GFP-MEG3 group compared with the pCMV6-A-GFP group and increased pGFP-V-RS-MEG3 group compared to pGFP-V-RS group, it was significantly not altered in pCMV6-A-GFP-MEG3+pGFP-V-RS-P53 group, pCMV6-A-GFP-MEG3+ pCMV6-A-GFP-HULC group, pGFP-V-RS-MEG3+pcDNA3-P53 group and the pGFP-V-RS-MEG3+pGFP-V-RS-HULC group (Figure 6G). Furthermore, although quantitative analysis of telomere length showed telomere length was significantly reduced in the pCMV6-A-GFP-MEG3 group compared with the pCMV6-A-GFP group (1.643±0.284 vs 0.243±0.042; P=0.00661<0.01) and increased pGFP-V-RS-MEG3 group compared to pGFP-V-RS group (1.513± 0.208 vs 4.21 ± 0.311; P=0.00602<0.01), it was significantly not altered in pCMV6-A-GFP-MEG3+pGFP-V-RS-P53 group (1.643±0.284 vs 1.347±0.185; P=0.10788>0.05), pCMV6-A-GFP-MEG3+pCMV6-A-GFP-HULC group (1.643±0.284 vs 1.527 ±0.105; P=0.296>0.05), pGFP-V-RS-MEG3+pcDNA3-P53-hLCSCs group (1.513±0.208 vs 1.313±0.138; P=0.071>0.05) and pGFP-V-RS-MEG3+pGFP-V-RS-HULC group (1.513±0.208 vs 1.446±0.197; P=0.178>0.05) compared with the pCMV6-A-GFP group (Figure 6H). Collectively, these results suggest that MEG3 inhibits telomere elongation dependent on both P53 and HULC in liver cancer stem cells.

The Excessive of TERT or TRF2 abrogates the inhibitory effect of MEG3 on the growth of human liver cancer stem cells

To address whether that MEG3 inhibits the growth of liver cancer stem cells is associated with TERT or TRF2. We constructed related cell lines and then performed rescued-experiments. Compared to pCMV6-A-GFP group, MEG3 was overexpressed in pCMV6-A-GFP-MEG3 group, pCMV6-A-GFP-MEG3+rLV-TERT group, pCMV6-A-GFP-MEG3+pGFP-V-RS-TERT group, pCMV6-A-GFP-MEG3+ telomerase inhibitor group, and the TERT expression was decreased in pCMV6-A-GFP-MEG3 group, pCMV6-A-GFP+ pGFP-V-RS-TERT group, pCMV6-A-GFP-MEG3+telomerase inhibitor group and increased in pCMV6-A-GFP-MEG3+rLV-TERT group (Figure 7A). Compared to pCMV6-A-GFP group, cell growth was inhibited in pCMV6-A-GFP-MEG3 group, pCMV6-A-GFP-MEG3 + pGFP-V-RS-TERT group, telomerase inhibitor group, pCMV6-A-GFP-MEG3+ telomerase inhibitor group and in pCMV6-A-GFP-MEG3+pGFP-V-RS group (P<0.01). There was no significant difference between pCMV6-A-GFP group and pCMV6-A-GFP-MEG3+rLV-TERT group (P>0.05). Moreover, cells proliferation was slower in the pCMV6-A-GFP-MEG3+pGFP-V-RS-TERT group, pCMV6-A-GFP-MEG3+ telomerase inhibitor group than in pCMV6-A-GFP group (Figure 7B). Compared with the pCMV6-A-GFP group, the colony formation rate was significantly decreased in the pCMV6-A-GFP-MEG3 group (18.86±3.79% vs 40.19±4.92%, P=0.00795<0.01), pCMV6-A-GFP-MEG3 + pGFP-V-RS-TERT group (9.52±1.54% vs 40.19±4.92%, P=0.0068<0.01), telomerase inhibitor group (21.19±4.52% vs 40.19±4.92%, P=0.028<0.05), pCMV6-A-GFP-MEG3+ telomerase inhibitor group (10.97±3.07% vs 40.19±4.92%, P=0.000724<0.01). Moreover, the colony formation rate was lower in the pCMV6-A-GFP-MEG3 + pGFP-V-RS-TERT group and the pCMV6-A-GFP-MEG3 + telomerase inhibitor group. However, there was no significant change between the pCMV6-A-GFP-MEG3 + rLV-TERT-hLCSCs group and pCMV6-A-GFP group (42.13 ± 2.77 % vs 40.19 ± 4.92%, P=0.336>0.05) (Fig. 7C). Figure 7Da shows photographs of transplanted tumors (xenograft). Compared to pCMV6-A-GFP group, the xenografts weight was significantly reduced in the pCMV6-A-GFP-MEG3
group (0.298±0.046g vs 0.837±0.079g, P=0.000022<0.01), pCMV6-A-GFP-MEG3 + pGFP-V-RS-TERT group (0.127±0.186g vs 0.837±0.079g, P=0.0000014<0.01), telomerase inhibitor group (0.28±0.0529g vs 0.837±0.079g, P=0.00000317<0.01). Moreover, the transplanted tumor weight was lower in the pCMV6-A-GFP-MEG3 + pGFP-V-RS-TERT group and the pCMV6-A-GFP-MEG3+ telomerase inhibitor group. However, there was no significant difference between pCMV6-A-GFP group and pCMV6-A-GFP-MEG3 + p rLV-TERT-hLCSCs group (0.892±0.048 g vs 0.837±0.079 g, P=0.1149>0.05) (Figure 7Db). The positive rate of PCNA was significantly reduced in the pCMV6-A-GFP-MEG3 group (31.32±7.46% vs 56.34±5.53%, P=0.00057<0.01), pCMV6-A-GFP-MEG3 + pGFP-V-RS-TERT group (13.81±2.91% vs 56.34±5.53%, P=0.00000423<0.01), telomerase inhibitor group (33.32±5.61% vs 56.34±5.53%, P=0.00000434<0.01) and pCMV6-A-GFP-MEG3+ telomerase inhibitor group (14.76±4.35% vs 56.34±5.53%, P=0.0000475<0.01). Moreover, the positive rate of PCNA was lower in the pCMV6-A-GFP-MEG3+pGFP-V-RS-TERT group and the pCMV6-A-GFP-MEG3+ telomerase inhibitor group. However, there was no significant significance between pCMV6-A-GFP group and the pCMV6-A-GFP-MEG3 + rLV-TERT-hLCSCs group (59.91 ± 5.28% vs 56.34 ± 5.53%, P = 0.1379 > 0.05) (Figure7Dc).

Furthermore, we also constructed three stable cell lines, including pCMV6-A-GFP group, pCMV6-A-GFP-MEG3 group, pCMV6-A-GFP-MEG3 + rLV-TRF2 group. As shown in Figure7E, compared to pCMV6-A-GFP group, MEG3 was significantly increased in pCMV6-A-GFP-MEG3 group, pCMV6-A-GFP-MEG3+rLV-TRF2 group, respectively. Compared to pCMV6-A-GFP group, the expression of TRF2 was decreased in pCMV6-A-GFP-MEG3 group and increased in pCMV6-A-GFP-MEG3+rLV-TRF2 group. Compared to pCMV6-A-GFP group, the growth ability was attenuated in pCMV6-A-GFP-MEG3 group(P<0.01). However, there was no significant difference of growth ability between pCMV6-A-GFP group and pCMV6-A-GFP-MEG3 + rLV-TRF2-hLCSCs group (Figure7F). Compared to pCMV6-A-GFP group, the colony formation rate was decreased in pCMV6-A-GFP-MEG3 group (11.34±2.05% vs 64.96±7.71%, P=0.00535<0.01). However, there was no significant difference between pCMV6-A-GFP group and pCMV6-A-GFP-MEG3+rLV-TRF2-hLCSCs group (68.89±5.76% vs 64.96). ± 7.71%, P =0.3224 > 0.05) (Figure7G). Compared to pCMV6-A-GFP group, the sphere formation rate was decreased in pCMV6-A-GFP-MEG3 group (11.85±3.93% vs 24.81±4.94%, P=0.000528<0.01). However, there was no significant difference between pCMV6-A-GFP group and pCMV6-A-GFP-MEG3+rLV-TRF2-hLCSCs group (26.04 ± 9.41% vs 24.81±4.94%, P=0.171>0.05) (Figure7H). Compared to pCMV6-A-GFP group, the xenograft tumor weight was significantly decreased in pCMV6-A-GFP-MEG3 group (0.86±0.108g vs 0.37±0.053 g, P=0.000175<0.01). However, there was no significant difference between pCMV6-A-GFP group and pCMV6-A-GFP-MEG3 + rLV-TRF2-hLCSCs group (0.915±0.1559 g vs 0.86±0.108 g, P=0.2143>0.05) (Figure7Ia&b). Compared to pCMV6-A-GFP group, the appearance time of xenograft tumor was increased in pCMV6-A-GFP-MEG3 group (14.33±1.75 days vs 7.83±1.17 days, P=0.00001124<0.01). However, there was no significant difference between pCMV6-A-GFP group and pCMV6-A-GFP-MEG3 + rLV-TRF2- hLCSCs group (8.33±1.37 days vs 7.83±1.17 days, P=0.2448> 0.05) (Figure7Ic). The PCNA positive rate was significantly reduced in pCMV6-A-GFP-MEG3 group (68.84±9.12% vs 68.84±9.12%, P=0.00001644<0.01). However, there was no significant difference between pCMV6-A-GFP group and pCMV6-A-GFP-MEG3+rLV-TRF2-hLCSCs group (72.82±6.82 days vs
68.84±9.12%, P= 0.18139>0.05) (Figure7ld). Collectively, these results suggest that excessive of TERT or TRF2 abrogates the inhibitory effect of MEG3 on the growth of human liver cancer stem cells.

Discussion

Long non-coding RNA MEG3 is a maternal-expressed imprinting gene involved in the regulation of various growth processes and plays an important role in inhibiting tumorigenesis.(55-58). For example, the expression of MEG3 in cancer cells is significantly reduced and inhibits cell viability (59,60). To date, our observations indicated that MEG3 increased the methylation modification of histone H3 at the 27th lysine in the TERT promoter region dependent on P53, thereby inhibiting the expression of TERT. Furthermore, MEG3 reduces the binding of TERC to TERT, thereby further inhibiting the activity of telomerase in human liver cancer stem cells. Moreover, MEG3 reduces the stability of telomere dependent on the interaction between P53 and HULC. Importantly, our findings demonstrated that both telomerase activity and telomere stabilizing protein TRF2 were important reasons for MEG3 inhibiting human liver cancer stem cells(Figure7J).

Notably, our results indicate that MEG3 inhibits the proliferation of human liver cancer stem cells in vitro and in vivo. According to research reports, excessive MEG3 can inhibit tumor growth through a variety of mechanisms. For example, MEG3 promotes apoptosis and the expression of the tumor suppressor gene P53(61-63). Furthermore, MEG3 inhibits tumor cell proliferation by blocking the Notch signaling pathway (64). Our results are consistent with these reports. A large number of studies have shown that there are liver cancer stem cells in liver cancer tissues, which have stem cell characteristics such as self-renewal and differentiation (65). It has been reported that a small number of liver cancer stem cells can be isolated from some human liver cancer cell lines, such as Huh7 (67). In this study, we used isolated and identified human liver cancer stem cell hLCSCs to reveal that MEG3 can inhibit the growth of human liver cancer stem cells on epigenetic mechanisms. It has been seen that MEG3 may inhibit the development of human liver cancer by altering several complex signaling pathways.

Our study demonstrates that MEG3 promotes the expression of the tumor suppressor gene P53. The primary mechanism is that MEG3 increases the binding ability of RNA polymerase II to the P53 promoter region. In particular, our results show that MEG3 can form a circular structure, which is likely forms a supercoiled topology to lead both RNA polymerase II and P300 to the transcriptional regulatory region of P53. Studies have shown that P53 is a multifunctional transcription factor that has been shown to be a very important tumor suppressor gene(68,69). Studies have shown that P53 can induce cell cycle arrest and promote DNA repair or induce apoptosis through multiple pathways (68). However, a large number of studies have shown that the mutation rate of P53 in human tumor cells is high, which are closely related to the occurrence of tumors (70-72). Importantly, our study reveals that MEG3 can affect the expression and function of telomere-related genes, such as telomerase reverse transcriptase TERT, telomerase RNA TERC, telomere repeat RNA sequence TERRA, telomere length maintenance protein POT1 Exo1, TRF2, SNM1B, CST/AAF, etc., However, knockdown of P53 abolishes the effect of MEG3 on the expression and function of these genes.
Studies have shown that changes in epigenetic modifications can cause changes in gene expression, which may ultimately affect cell fate (73). Our results indicate that MEG3 is involved in epigenetic modification of histones. The main evidences are as follows: (a) MEG3 increases methylation of at the 27th lysine of histone H3 (H3K27me1/2/3) dependent on P53. (b) The function of MEG3 requires the participation of the epigenetic modification factor heterochromatin protein HP1α. (c) MEG3 regulates several long non-coding RNAs (such as TERC, TERRA, HULC). In particular, MEG3 promotes the binding of P53 and HP1α to telomerase RNA TERC, reducing the binding of TERT to TERC competitively. In addition, MEG3 promotes the expression of long non-coding RNA TERRA, increasing the binding of TERT to TERRA. Furthermore, MEG3 regulates telomere lifespan involving in the long non-coding RNA HULC. In this study, our findings suggest that MEG3 promotes the binding of P300 to the P53 promoter region. P300 is a histone acetyltransferase that catalyzes the acetylation of histones and promotes gene expression (74). It can be seen that MEG3 may promote the acetylation of histones in the P53 promoter, increasing transcriptional activity of P53.

Interestingly, our study indicate that MEG3 promotes the interaction between PRC2 complex and histone H3, which in turn promotes methylation of histone H3 at the 27th lysine (H3K27me1/2/3). The PRC2 complex (EZH2, SUZ12, EED, RbAp46/48) is a chromatin-binding complex with histone modification activity, which catalyzes the methylation modification of the 27th lysine of histone H3 and results in transcriptional repression of several genes (75-77). Studies have shown that H3K27me3 alters the expression of certain differentiation-related genes, which contributes to the malignant proliferation of tumors (78). Moreover, high expression of EZH2 in prostate cancer cells increases the level of histone H3K27me3 in the promoter region of the tumor suppressor gene ID4 (79). Therefore, MEG3 alters the expression of certain genes dependent on histone H3K27 methylation, such as reverse transcriptase TERT. Furthermore, we also indicate that MEG3 enhances the TERRA expression by altering the epigenetic modification of the TERRA promoter region by affecting DNA methyltransferase activity in human liver cancer stem cells.

It is worth noting that the heterochromatin protein HP1α regulates the function of MEG3 in human liver stem cells. Knockdown of HP1α in MEG3 overexpressing human liver cancer stem cells inhibits the binding of MEG3 to P53. HP1α is a heterochromatin protein that recognizes the methylation status of histone H3K9 (80). Numerous studies have shown that HP1α has dual regulatory effects in tumor cells. For example, up-regulation of HP1α is associated with accelerated proliferation of tumor cells (81). Several reports have shown that HP1α can promote the level of H3K9me3 in the tumor suppressor gene promoter region (82).

Furthermore, telomeres are special nuclear protein structures at the ends of eukaryotic chromosomes, thereby maintaining genome stability (83). In most somatic cells, the telomere length of a chromosome becomes shorter as the number of cell divisions increases (84). Our findings indicate that MEG3 inhibits telomerase activity in human liver cancer stem cells. The main evidences include: (a) MEG3 significantly increased the H3K27me3 modification of the telomerase reverse transcriptase TERT promoter, reduced the binding of RNA pol II to the TERT promoter, and ultimately inhibited the expression of TERT at the
transcriptional level. (b) MEG3 competitively reduces the binding of TERT to telomerase RNA TERC via P53 and HP1α. (c) MEG3 promotes the binding of P300 and RNA pol II to the long-chain non-coding RNA TERRA promoter, promotes TERRA expression at the transcriptional level, and ultimately inhibits telomerase activity. Studies have shown that TERRA is a long-chain non-coding RNA encoded by telomere DNA and dependent on RNA polymerase II (85). TERT and TERC together constitute active telomerase (86). Studies have reported that TERRA can bind to TERC through the principle of base-complementary pairing (87). Our study suggests that MEG3 promotes the expression of TERRA and thus enhances the binding of TERRA to TERT, competitively inhibits the interaction of TERC with TERT, and ultimately inhibits telomerase activity in human liver cancer stem cells.

Strikingly, our study also found that although MEG3 inhibited the growth of human liver cancer stem cells, the excess of telomerase reverse transcriptase TERT abolished the tumor suppressor function of MEG3. Thus, the tumor suppressor function of MEG3 is closely related to the activity of telomerase. Studies have shown that telomerase is a reverse transcriptase that adds telomere repeats to the ends of chromosomes (88). Numerous studies have shown that telomerase activity is increased in a variety of tumor cells, and that increased telomerase activity is associated with increased copy number of telomerase core members TERC and TERT genes (89). Therefore, MEG3 reduces the activity of telomerase by inhibiting the expression of telomerase member TERT or by promoting the competitive inhibition of TERRA expression by binding of TERC to TERT.

Furthermore, our results also indicate that MEG3 regulates the length of telomeres in human liver cancer stem cells. The main basis is as follows: (a) MEG3 increased the binding of CST/AAF to telomere protein POT1, and decreased the interaction between TRF2 and SNM1B, and inhibited the formation of telomere length maintenance complex. (b) MEG3 reduces the stability of telomeres by inhibiting the combination of telomere structure by inhibiting telomere length (including POT1, Exo1, TRF2, SNM1B). (c) MEG3 increased the binding of P53 to long-chain non-coding RNA HULC, thereby inhibiting the formation of telomere length maintenance complex and its ability to bind to telomeres. (d) Although MEG3 inhibited the proliferation of human liver cancer stem cells, the excess of the telomere length maintenance protein TRF2 abolished the tumor suppressor function of MEG3. It can be seen that MEG3 reduces the length of telomeres and shortens the telomere life by a variety of mechanisms.

Importantly, our results suggest that MEG3 controls telomere length and is closely related to HULC. Studies have shown that HULC is a long- noncoding RNA that is highly expressed in a variety of tumors (90). In our previous study, we found that HULC can form a complex with the telomere length maintenance protein TRF2 and bind to the telomere structure, replacing the CST/AAF protein on the telomere and recruiting telomere-associated proteins POT1, Exo1, and SNM1B. The stability of telomeres ultimately promotes the malignant proliferation of liver cancer stem cells (91). Our results show that HULC can promote the formation of telomere length maintenance complex and its binding to telomere structure, however, HULC knockdown abolishes these functions. We also found that MEG3 significantly promoted the interaction of P53 with HULC in liver cancer stem cells, thereby competitively reducing the binding ability of POT1, Exo1, TRF2, SNM1B and HULC. Moreover, P53 knockdown can increase the
binding of POT1, Exo1, TRF2, SNM1B to telomeric DNA. Therefore, MEG3 inhibits the binding of telomere length maintenance complex POT1-Exo1-TRF2-SNM1B to telomeric DNA dependent on the interaction between P53 and HULC, which reduces the stability of telomeres and shortens telomere lifespan in human liver cancer stem cells.

In summary, our studies reveal that MEG3 significantly inhibits the growth of human liver cancer stem cells in vitro and in vivo. MEG3 promotes the expression of P53, which promotes methylation of histone H3 on the 27th lysine, inhibiting the transcriptional activity of TERT. At the same time, MEG3 inhibits telomerase activity in human liver cancer stem cells by reducing the binding of TERT to TERC. In addition, MEG3 promotes the interaction between P53 and HULC, which inhibits the binding of telomere length maintenance complex POT1-Exo1-TRF2-SNM1B to telomeric DNA, and finally inhibits the length of telomeres in human liver cancer stem cells. Therefore, MEG3 inhibits the activity of telomerase and shortens the length of telomeres, thereby inhibiting the malignant progression of human liver cancer. These results provide important theoretical basis for the prevention and treatment of human liver cancer. However, we also need to continue to explore a more detailed mechanism of MEG3 action.

Conclusions

MEG3 inhibited the growth in vitro and in vivo of hLCSCs by reducing the activity of telomerase and attenuating telomeric repeat binding factor 2 (TRF2). Our results demonstrate MEG3 inhibits the occurrence of human liver cancer and these findings provide an important insight into the prevention and treatment of human liver cancer.

Declarations

Ethics approval and consent to participate

All methods were carried out in "accordance" with the approved guidelines. All experimental protocols "were approved by" a Tongji university institutional committee. Informed consent was obtained from all subjects. The study was reviewed and approved by the China national institutional animal care and use committee.

Consent for publication

'Not applicable'

Availability of data and material

'Not applicable'

Competing interests

"The authors declare that they have no competing interests"
Funding and Acknowledgements

This study was supported by grants from National Natural Science Fundation of China (NCSF No.8127229181773158) and National Natural Science Fundation of China (NCSF No.8127229182073130) and by grants from Science and Technology Commission of Shanghai Municipality Shanghai Science and Technology Plan Basic Research Field Project 19JC1415200 and by grants from Science and Technology Commission of Shanghai Municipality Shanghai Science and Technology Plan Basic Research Field Project 20JC1411400.

Authors' contributions

Dongdong Lu conceived the study and participated in the study design, performance, coordination and manuscript writing. Xiaoxue Jiang, Liyan Wang, Sijie Xie, Yingjie Chen, Shuting Song, Yanan Lu performed the research. All authors have read and approved the final manuscript.

Abbreviations

telomerase reverse transcriptase (TERT)
telomerase RNA (TERC)
TERRA (Telomeric Repeat-Containing RNA)
heterochromatin 1 (HP1)
interstitial Heterochromatin (PCH)
polycomb Repressive Complex 2 (PRC2)
the methylation of the 27th lysine of histone H3 (H3K27me2/3)
hepatocellular carcinoma (HCC)
intrahepatic cholangiocarcinoma (ICC)
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
Chromosome conformation capture -chromatin immunoprecipitation ((3C-ChIP)
proliferating cell nuclear antigen (PCNA)
human hepatoma stem cell lines (hLCSCs)

References
1. Rosental B, Kowarsky M, Seita J, Corey DM, Ishizuka KJ, Palmeri KJ, Chen SY, Sinha R, Okamoto J, Mantalas G, Manni L, Raveh T, Clarke DN, Tsai JM, Newman AM, Neff NF, Nolan GP, Quake SR, Weissman IL, Voskoboynik A. Complex mammalian-like haematopoietic system found in a colonial chordate. Nature. 2018;564(7736):425-429

2. Messal HA, Alt S, Ferreira RMM, Gribben C, Wang VM, Cotoi CG, Salbreux G, Behrens A. Tissue curvature and apicobasal mechanical tension imbalance instruct cancer morphogenesis. Nature. 2019;566(7742):126-130.

3. Sánchez-Danés A, Larsimont JC, Liagre M, Muñoz-Couselo E, Lapouge G, Brisebarre A, Dubois C, Suppa M, Sukumaran V, Del Marmol V, Tabernero J, Blanpain C. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. Nature. 2018;562(7727):434-438

4. Mrna Choe J, Lin S, Zhang W, Liu Q, Wang L, Ramirez-Moya J, Du P, Kim W, Tang S, Sliz P, Santisteban P, George RE, Richards WG, Wong KK, Locker N, Slack FJ, Gregory RI. mRNA circularization by METTL3-elf3h enhances translation and promotes oncogenesis. Nature. 2018;561(7724):556-560

5. Fu T, Coulter S, Yoshihara E, Oh TG, Fang S, Cayabyab F, Zhu Q, Zhang T, Leblanc M, Liu S, He M, Waizenegger W, Gasser E, Schnabl B, Atkins AR, Yu RT, Knight R, Liddle C, Downes M, Evans RM. FXR Regulates Intestinal Cancer Stem Cell Proliferation. Cell. 2019;176(5):1098-1112.

6. Gronke K, Hernández PP, Zimmermann J, Klose CSN, Kofoed-Branzak M, Guendel F, Witkowski M, Tizian C, Amann L, Schumacher F, Glatt H, Triantafyllopoulou A, Diefenbach A. Interleukin-22 protects intestinal stem cells against genotoxic stress. Nature. 2019;566(7743):249-253

7. Bahr C, von Paleske L, Uslu VV, Remeseiro S, Takayama N, Ng SW, Murison A, Langenfeld K, Petretich M, Scognamiglio R, Zeisberger P, Benk AS, Amit I, Zandstra PW, Lupien M, Dick JE, Trumpp A, Spitz F. A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies. Nature. 2018;553(7689):515-520.

8. Xu XL, Xing BC, Han HB, et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient’s primary and recurrent tumor. Carcinogenesis, 2010, 31(2): 167-174.

9. Blackburn EH. Structure and function of telomeres. Nature, 1991, 350(6319): 569-573.

10. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annual review of genetics, 2008, 42: 301-334.

11. Galati A, Micheli E, Alicata C, et al. TRF1 and TRF2 binding to telomeres is modulated by nucleosomal organization. Nucleic acids research, 2015, 43(12): 5824-5837.

12. Stone MD. Detailed view of human telomerase enzyme invites rethink of its structure. Nature. 2018;557(7704):174-175
13. Blackburn EH EE, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science, 2015, 350(6265): 1193-1198.

14. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. European journal of cancer, 1997, 33(5): 787-791.

15. Zaret KS. The telomerase enzyme and liver renewal. Nature. 2018;556(7700):181-182

16. Wang S, Pike AM, Lee SS, et al. BRD4 inhibitors block telomere elongation. Nucleic acids research, 2017, 45(14): 8403-8410.

17. Benetti R, Garcia-Cao M, Blasco MA. Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres. Nature genetics, 2007, 39(2): 243-250.

18. Azzalin CM, Reichenbach P, Khoriauli L, et al. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science, 2007, 318(5851): 798-801.

19. Cusanelli E, Chartrand P. Telomeric repeat-containing RNA TERRA: a noncoding RNA connecting telomere biology to genome integrity. Frontiers in genetics, 2015, 6: 143.

20. Deng Z, Norseen J, Wiedmer A, et al. TERRA RNA binding to TRF2 facilitates heterochromatin formation and ORC recruitment at telomeres. Molecular cell, 2009, 35(4): 403-413.

21. Redon S, Reichenbach P, Lingner J. The non-coding RNA TERRA is a natural ligand and direct inhibitor of human telomerase. Nucleic acids research, 2010, 38(17): 5797-5806.

22. Redon S, Zemp I, Lingner J. A three-state model for the regulation of telomerase by TERRA and hnRNPA1. Nucleic acids research, 2013, 41(19): 9117-9128.

23. Zhang JM, Yadav T, Ouyang J, Lan L, Zou L. Alternative Lengthening of Telomeres through Two Distinct Break-Induced Replication Pathways. Cell Rep. 2019;26(4):955-968

24. Dilley RL, Verma P, Cho NW, Winters HD, Wondisford AR, Greenberg RA. Break-induced telomere synthesis underlie alternative telomere maintenance. Nature. 2016;539(7627):54-58

25. Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK, Olivieri M, Álvarez-Quilón A, Moatti N, Zimmermann M, Annunziato S, Krastev DB, Song F, Brandsma I, Frankum J, Brough R, Sherker A, Landry S, Szilard RK, Munro MM, McEwan A, Goulet de Rugy T, Lin ZY, Hart T, Moffat J, Gingras AC, Martin A, van Attikum H, Jonkers J, Lord CJ, Rottenberg S, Durocher D. The shieldin complex mediates 53BP1-dependent DNA repair. Nature. 2018;560(7716):117-121

26. Zlotorynski E. Telomere crisis activates autophagic death. Nat Rev Mol Cell Biol. 2019;20(3):133

27. Cubiles MD, Barroso S, Vaquero-Sedas MI, Enguix A, Aguilera A, Vega-Palas MA. Epigenetic features of human telomeres. Nucleic Acids Res. 2018;46(5):2347-2355
28. Schmidt JC, Zaug AJ, Cech TR. Live Cell Imaging Reveals the Dynamics of Telomerase Recruitment to Telomeres. Cell 2016;166(5):1188-1197

29. Zhou Y, Cheunsuchon P, Nakayama Y, et al. Activation of paternally expressed genes and perinatal death caused by deletion of the Gtl2 gene. Development, 2010, 137(16): 2643-2652.

30. Stadtfeld M, Apostolou E, Akutsu H, Fukuda A, Follett P, Natesan S, Kono T, Shioda T, Hochedlinger K. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010;465(7295):175-81

31. Yu F, Geng W, Dong P, Huang Z, Zheng J. LncRNA-MEG3 inhibits activation of hepatic stellate cells through SMO protein and miR-212. Cell Death Dis. 2018;9(10):1014

32. Huang P, Huang FZ, Liu HZ, Zhang TY, Yang MS, Sun CZ. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6. Metabolism. 2019 Jan 31. pii: S0026-0495(19)30033-2.

33. Zhang X, Rice K, Wang Y, et al. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology, 2010, 151(3): 939-947.

34. Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. Journal of molecular endocrinology, 2012, 48(3): R45-53.

35. Yan J, Guo X, Xia J, et al. MiR-148a regulates MEG3 in gastric cancer by targeting DNA methyltransferase 1. Medical oncology, 2014, 31(3): 879.

36. Liu LX, Deng W, Zhou XT, et al. The mechanism of adenosine-mediated activation of lncRNA MEG3 and its antitumor effects in human hepatoma cells. International journal of oncology, 2016, 48(1): 421-429.

37. Zhou Y, Zhong Y, Wang Y, et al. Activation of p53 by MEG3 non-coding RNA. The Journal of biological chemistry, 2007, 282(34): 24731-24742.

38. Wu M, Huang Y, Chen T, Wang W, Yang S, Ye Z, Xi X. LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis. J Cell Mol Med. 2019;23(1):29-38

39. Zhang Y, Wu J, Jing H, Huang G, Sun Z, Xu S. Long noncoding RNA MEG3 inhibits breast cancer growth via upregulating endoplasmic reticulum stress and activating NF-κB and p53. J Cell Biochem. 2019;120(4):6789-6797

40. Jiang M, Wang YR, Xu N, Zhou L, An Q. Long noncoding RNA MEG3 play an important role in osteosarcoma development through sponging microRNAs. J Cell Biochem. 2019;120(4):5151-5159.
41. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell death and differentiation, 2006, 13(6): 941-950.

42. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene, 2005, 24(17): 2899-2908.

43. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell, 2009, 137(3): 413-431.

44. Ghezraoui H, Oliveira C, Becker JR, Bilham K, Moralli D, Anzilotti C, Fischer R, Deobagkar-Lele M, Sanchiz-Calvo M, Fueyo-Marcos E, Bonham S, Kessler BM, Rottenberg S, Cornall RJ, Green CM, Chapman JR. 53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ. *Nature*. 2018;560(7716):122-127.

45. Maya-Mendoza A, Moudry P, Merchut-Mayaj JM, Lee M, Strauss R, Bartek J. High speed of fork progression induces DNA replication stress and genomic instability. *Nature*. 2018;559(7713):279-284.

46. Canzio D, Larson A, Narlikar GJ. Mechanisms of functional promiscuity by HP1 proteins. Trends in cell biology, 2014, 24(6): 377-386.

47. Maison C, Almouzni G. HP1 and the dynamics of heterochromatin maintenance. *Nature reviews Molecular cell biology*, 2004, 5(4): 296-304.

48. Eissenberg JC, Elgin SC. HP1a: a structural chromosomal protein regulating transcription. Trends in genetics : TIG, 2014, 30(3): 103-110.

49. Bosch-Presegue L, Raurell-Vila H, Thackray JK, et al. Mammalian HP1 Isoforms Have Specific Roles in Heterochromatin Structure and Organization. *Cell reports*, 2017, 21(8): 2048-2057.

50. Jensen KN, Lorincz MC. HP1 proteins safeguard embryonic stem cells. *Nature*. 2018;557(7707):640-641.

51. Ostapcuk V, Mohn F, Carl SH, Basters A, Hess D, Iesmantavicius V, Lampersberger L, Flemr M, Pandey A, Thomä NH, Betschinger J, Bühler M. Activity-dependent neuroprotective protein recruits HP1 and CHD4 to control lineage-specifying genes. *Nature*. 2018;557(7707):739-743.

52. Vizan P, Beringer M, Ballare C, et al. Role of PRC2-associated factors in stem cells and disease. The FEBS journal, 2015, 282(9): 1723-1735.

53. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. *Nature*, 2011, 469(7330): 343-349.

54. Liu YL, Gao X, Jiang Y, et al. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer. Journal of cancer research and clinical oncology, 2015, 141(4): 661-669.
55. Manji SS, Sorensen BS, Klockars TI. Molecular characterization and expression of maternally expressed gene 3 (Meg3/Gtl2) RNA in the mouse inner ear. Journal of neuroscience research, 2006, 83(2): 181-190.

56. Zhou Y, Cheunsuchon P, Nakayama Y. Activation of paternally expressed genes and perinatal death caused by deletion of the Gtl2 gene. Development, 2010, 137(16): 2643-2652.

57. He Y, Wu YT, Huang C. Inhibitory effects of long noncoding RNA MEG3 on hepatic stellate cells activation and liver fibrogenesis. Biochimica et biophysica acta, 2014, 1842(11): 2204-2215.

58. Chak WP, Lung RW, Tong JH. Downregulation of long non-coding RNA MEG3 in nasopharyngeal carcinoma. Molecular carcinogenesis, 2017, 56(3): 1041-1054.

59. Ying L, Huang Y, Chen H, et al. Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. Molecular bioSystems, 2013, 9(3): 407-411.

60. Sun M, Xia R, Jin F, et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, 35(2): 1065-1073.

61. Lu KH LW, Liu XH, Sun M, et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer, 2013, 13: 461.

62. Li J, Bian EB, He XJ, et al. Epigenetic repression of long non-coding RNA MEG3 mediated by DNMT1 represses the p53 pathway in gliomas. International journal of oncology, 2016, 48(2): 723-733.

63. Qin R, Chen Z, Ding Y, et al. Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. Neoplasma, 2013, 60(5): 486-492.

64. Guo Q, Qian Z, Yan D, et al. LncRNA-MEG3 inhibits cell proliferation of endometrial carcinoma by repressing Notch signaling. Biomedicine & pharmacotherapy, 2016, 82: 589-594.

65. Xu XL, Xing BC, Han HB, et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. Carcinogenesis, 2010, 31(2): 167-174.

66. Li J, Chen JN, Zeng TT, et al. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy. BMC cancer, 2016, 16: 15.

67. Pflaum J, Schlosser S, Muller M. p53 Family and Cellular Stress Responses in Cancer. Frontiers in oncology, 2014, 4: 285.

68. Pflaum J, Schlosser S, Muller M. p53 Family and Cellular Stress Responses in Cancer. Frontiers in oncology, 2014, 4: 285.
69 Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell death and differentiation, 2006, 13(6): 941-950.

70. Basu S, Murphy ME. Genetic Modifiers of the p53 Pathway. Cold Spring Harbor perspectives in medicine, 2016, 6(4): a026302.

71. Liou AT, Chen MF, Yang CW. Curcumin Induces p53-Null Hepatoma Cell Line Hep3B Apoptosis through the AKT-PTEN-FOXO4 Pathway. Evidence-based complementary and alternative medicine : eCAM, 2017, 2017: 4063865.

72. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochemical and biophysical research communications, 2005, 331(3): 834-842

73. Deshmukh A, Binju M, Arfuso F, et al. Role of epigenetic modulation in cancer stem cell fate. The international journal of biochemistry & cell biology, 2017, 90: 9-16.

74. Chan WM, Mak MC, Fung TK, et al. Ubiquitination of p53 at multiple sites in the DNA-binding domain. Molecular cancer research: MCR, 2006, 4(1): 15-25

75. Vizan P, Beringer M, Ballare C, et al. Role of PRC2-associated factors in stem cells and disease. The FEBS journal, 2015, 282(9): 1723-1735.

76. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature, 2011, 469(7330): 343-349.

77. Margueron R, Li G, Sarma K, et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Molecular cell, 2008, 32(4): 503-518.

78. Conway E, Healy E, Bracken AP. PRC2 mediated H3K27 methylations in cellular identity and cancer. Current opinion in cell biology, 2015, 37: 42-48.

79. Chinaranagari S, Sharma P, Chaudhary J. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer. Oncotarget, 2014, 5(16): 7172-7182.

80. Eissenberg JC, Elgin SC. HP1a: a structural chromosomal protein regulating transcription. Trends in genetics: TIG, 2014, 30(3): 103-110.

81. Kirschmann DA, Lininger RA, Gardner LM, et al. Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer. Cancer research, 2000, 60(13): 3359-3363.

82. Cheng W, Tian L, Wang B, et al. Downregulation of HP1alpha suppresses proliferation of cholangiocarcinoma by restoring SFRP1 expression. Oncotarget, 2016, 7(30): 48107-48119.

83. Wang L, Xiao H, Zhang X, et al. The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. Journal of hematology & oncology, 2014, 7: 61.
84. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature, 1990, 345(6274): 458-460.

85. Azzalin CM, Reichenbach P, Khoriauli L, et al. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science, 2007, 318(5851): 798-801.

86. Blackburn EH EE, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science, 2015, 350(6265): 1193-1198.

87. Redon S, Reichenbach P, Lingner J. The non-coding RNA TERRA is a natural ligand and direct inhibitor of human telomerase. Nucleic acids research, 2010, 38(17): 5797-5806.

88. Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature, 1989, 337(6205): 331-337.

89. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. European journal of cancer, 1997, 33(5): 787-791.

90. Yu X, Zheng H, Chan MT, et al. HULC: an oncogenic long non-coding RNA in human cancer. Journal of cellular and molecular medicine, 2017, 21(2): 410-417.

91. Wu M, Lin Z, Li X, et al. HULC cooperates with MALAT1 to aggravate liver cancer stem cells growth through telomere repeat-binding factor 2. Scientific reports, 2016, 6: 36045.